adenine has been researched along with Thrombopenia in 16 studies
Excerpt | Relevance | Reference |
---|---|---|
"A 56-year-old male patient received adefovir dipivoxil (10 mg/day) for chronic hepatitis B resistant to lamivudine." | 7.73 | Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B. ( Amato, A; Gaeta, GB; Stornaiuolo, G, 2006) |
"A 56-year-old male patient received adefovir dipivoxil (10 mg/day) for chronic hepatitis B resistant to lamivudine." | 3.73 | Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B. ( Amato, A; Gaeta, GB; Stornaiuolo, G, 2006) |
"After minimal residual disease-guided treatment (day 1 of month 16), 84 (62%, 90% CI 55-69) of 135 patients (ITT population) achieved a complete response with bone marrow minimal residual disease of less than 0·01%." | 2.90 | Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. ( Aanei, C; Aurran, T; Banos, A; Carassou, P; Cartron, G; Cymbalista, F; Dartigeas, C; de Guibert, S; Delmer, A; Dilhuydy, MS; Feugier, P; Fornecker, LM; Laribi, K; Le Garff-Tavernier, M; Leblond, V; Lepretre, S; Letestu, R; Lévy, V; Mahe, B; Michallet, AS; Nguyen-Khac, F; Orsini, F; Pegourie, B; Portois, C; Rouille, V; Salles, G; Subtil, F; Ticchioni, M; Tomowiak, C; Tournilhac, O; Truchan Graczyk, M; Villemagne, B; Vilque, JP; Ysebaert, L, 2019) |
"Between Sept 19, 2012, and Jan 21, 2014, 578 eligible patients were randomly assigned to ibrutinib or placebo in combination with bendamustine plus rituximab (289 in each group)." | 2.82 | Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. ( Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mato, A; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D, 2016) |
"Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration." | 2.53 | [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. ( Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S, 2016) |
"Familial macrothrombocytopenias are a group of rare autosomal dominant platelet disorders including many syndromes in particular the May-Hegglin anomaly." | 1.33 | [The MYH9 syndrome: report of a new case with a new mutation of the MYH9 gene]. ( Bardet, V; Berda-Haddad, Y; Bernit, E; Camoin, L; Difeo, A; Ebbo, M; Favier, R; Harle, JR; Heudier, P; Kaplanski, G; Mazodier, K; Schleinitz, N; Veit, V, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (25.00) | 18.7374 |
1990's | 2 (12.50) | 18.2507 |
2000's | 2 (12.50) | 29.6817 |
2010's | 6 (37.50) | 24.3611 |
2020's | 2 (12.50) | 2.80 |
Authors | Studies |
---|---|
Wang, ML | 1 |
Jain, P | 1 |
Zhao, S | 1 |
Lee, HJ | 1 |
Nastoupil, L | 1 |
Fayad, L | 1 |
Ok, CY | 1 |
Kanagal-Shamanna, R | 1 |
Hill, HA | 1 |
Yao, Y | 1 |
Hagemeister, FB | 1 |
Westin, JR | 1 |
Fowler, N | 1 |
Samaniego, F | 1 |
Steiner, R | 1 |
Nair, R | 1 |
Iyer, SP | 1 |
Navsaria, L | 1 |
Badillo, M | 1 |
Feng, L | 1 |
Xuelin, H | 1 |
Nogueras Gonzalez, GM | 1 |
Xu, G | 1 |
Wagner-Bartak, N | 1 |
Thirumurthi, S | 1 |
Santos, D | 1 |
Tang, G | 1 |
Lin, P | 1 |
Wang, SA | 1 |
Jorgensen, J | 1 |
Yin, CC | 1 |
Li, S | 1 |
Patel, KP | 1 |
Vega, F | 1 |
Medeiros, LJ | 1 |
Flowers, CR | 1 |
Wang, L | 1 |
Rogers, KA | 1 |
Huang, Y | 1 |
Ruppert, AS | 1 |
Abruzzo, LV | 1 |
Andersen, BL | 1 |
Awan, FT | 1 |
Bhat, SA | 1 |
Dean, A | 1 |
Lucas, M | 1 |
Banks, C | 1 |
Grantier, C | 1 |
Heerema, NA | 1 |
Lozanski, G | 1 |
Maddocks, KJ | 1 |
Valentine, TR | 1 |
Weiss, DM | 1 |
Jones, JA | 1 |
Woyach, JA | 1 |
Byrd, JC | 1 |
Law, YXT | 1 |
Lee, LS | 1 |
Michallet, AS | 1 |
Dilhuydy, MS | 2 |
Subtil, F | 1 |
Rouille, V | 1 |
Mahe, B | 1 |
Laribi, K | 1 |
Villemagne, B | 1 |
Salles, G | 1 |
Tournilhac, O | 1 |
Delmer, A | 1 |
Portois, C | 1 |
Pegourie, B | 1 |
Leblond, V | 1 |
Tomowiak, C | 1 |
de Guibert, S | 1 |
Orsini, F | 1 |
Banos, A | 1 |
Carassou, P | 1 |
Cartron, G | 1 |
Fornecker, LM | 1 |
Ysebaert, L | 1 |
Dartigeas, C | 1 |
Truchan Graczyk, M | 1 |
Vilque, JP | 1 |
Aurran, T | 1 |
Cymbalista, F | 1 |
Lepretre, S | 1 |
Lévy, V | 1 |
Nguyen-Khac, F | 1 |
Le Garff-Tavernier, M | 1 |
Aanei, C | 1 |
Ticchioni, M | 1 |
Letestu, R | 1 |
Feugier, P | 1 |
Herishanu, Y | 1 |
Katz, BZ | 1 |
Chanan-Khan, A | 1 |
Cramer, P | 1 |
Demirkan, F | 1 |
Fraser, G | 1 |
Silva, RS | 1 |
Grosicki, S | 1 |
Pristupa, A | 1 |
Janssens, A | 1 |
Mayer, J | 2 |
Bartlett, NL | 1 |
Pylypenko, H | 1 |
Loscertales, J | 1 |
Avigdor, A | 1 |
Rule, S | 1 |
Villa, D | 1 |
Samoilova, O | 1 |
Panagiotidis, P | 1 |
Goy, A | 1 |
Mato, A | 1 |
Pavlovsky, MA | 1 |
Karlsson, C | 1 |
Mahler, M | 1 |
Salman, M | 1 |
Sun, S | 1 |
Phelps, C | 1 |
Balasubramanian, S | 1 |
Howes, A | 1 |
Hallek, M | 1 |
Adam, Z | 1 |
Pour, L | 1 |
Krejčí, M | 1 |
Ševčíková, S | 1 |
Pourová, E | 1 |
Ševčíková, E | 1 |
Král, Z | 1 |
Quach, H | 1 |
Lee, LY | 1 |
Smith, B | 1 |
Korman, T | 1 |
Woolley, IJ | 1 |
CANCI, A | 1 |
JOHNSON, SA | 1 |
GREENWALT, TJ | 1 |
ARNAUD, SB | 1 |
PAWLOWSKI, JM | 1 |
Stornaiuolo, G | 1 |
Amato, A | 1 |
Gaeta, GB | 1 |
Schleinitz, N | 1 |
Favier, R | 1 |
Mazodier, K | 1 |
Difeo, A | 1 |
Ebbo, M | 1 |
Veit, V | 1 |
Berda-Haddad, Y | 1 |
Bernit, E | 1 |
Heudier, P | 1 |
Kaplanski, G | 1 |
Camoin, L | 1 |
Bardet, V | 1 |
Harle, JR | 1 |
Asbury, R | 1 |
Blessing, JA | 1 |
Podczaski, E | 1 |
Ball, H | 1 |
Cowan, DH | 1 |
Graham, RC | 1 |
Hanson, KH | 1 |
Crowley, J | 1 |
Salmon, SE | 1 |
Keppen, M | 1 |
Braun, TJ | 1 |
Bonnet, JD | 1 |
Hellem, AJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy[NCT02427620] | Phase 2 | 131 participants (Anticipated) | Interventional | 2015-06-03 | Active, not recruiting | ||
Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)[NCT02427451] | Phase 1/Phase 2 | 87 participants (Actual) | Interventional | 2015-08-03 | Active, not recruiting | ||
"Phase II, Multicenter, Trial, Exploring Chemo-free Treatment (GA101+Ibrutinib) and MRD-driven Strategy in Previously Untreated Symptomatic B-chronic Lymphocytic Leukemia Medically Fit A Study From the Goelams/GCFLLC/MW Intergroup"[NCT02666898] | Phase 2 | 135 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic[NCT01611090] | Phase 3 | 578 participants (Actual) | Interventional | 2012-09-19 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported. (NCT01611090)
Timeframe: Baseline to EOT (Up to 2 years)
Intervention | milligram per liter (mg/L) (Mean) |
---|---|
Ibrutinib+BR | -0.46 |
Placebo+BR | -0.23 |
"EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from 1 = not at all to 4 = very much. Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which was rated on a 7-point scale ranging from 1 = very poor to 7 = excellent. Lower scores indicate worsening. All scale and item scores were linearly transformed to be in range from 0-100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms." (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on a scale (Mean) |
---|---|
Ibrutinib+BR | -2.1 |
Placebo+BR | -4.1 |
The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1. High score indicating a high level of utility. (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on a scale (Mean) |
---|---|
Ibrutinib+BR | 0.0 |
Placebo+BR | 0.0 |
The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on a scale (Mean) |
---|---|
Ibrutinib+BR | -4.3 |
Placebo+BR | 4.0 |
FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on a scale (Mean) |
---|---|
Ibrutinib+BR | -0.9 |
Placebo+BR | 0.0 |
Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). (NCT01611090)
Timeframe: Up to 2 years
Intervention | Months (Number) |
---|---|
Ibrutinib+BR | 6.5 |
Placebo+BR | 4.6 |
Number of participants who received subsequent antineoplastic therapy was reported. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Participants (Count of Participants) |
---|---|
Ibrutinib+BR | 52 |
Placebo+BR | 61 |
The disease-related symptoms included fatigue, weight loss, fevers, night sweats, abdominal discomfort/splenomegaly and anorexia. (NCT01611090)
Timeframe: From the date of randomization to disease progression (Up to 2 years)
Intervention | Participants (Count of Participants) |
---|---|
Ibrutinib+BR | 0 |
Placebo+BR | 0 |
ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils >1.5*10^9/liter (L), platelets >100*10^9/L, Hgb >11 gram per deciliter (g/dL) and absolute lymphocyte count <4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: >=50% decrease in ALC, >=50% decrease in sum products of up to 6 lymph nodes, >=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils >1.5*10^9/L, Platelets >100*10^9/L and Hgb>11 g/dL or >=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Percentage of participants (Number) |
---|---|
Ibrutinib+BR | 87.2 |
Placebo+BR | 66.1 |
OS was defined as the interval between the date of randomization and the date of death from any cause. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Months (Median) |
---|---|
Ibrutinib+BR | NA |
Placebo+BR | NA |
MRD-negative response was defined as the percentage of participants who reach MRD negative disease status (less than 1 chronic lymphocytic leukemia [CLL] cell per 10,000 leukocytes) in either bone marrow or peripheral blood. All randomized participants were included in this analysis. Participants with missing MRD data were considered non-responders. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Percentage of participants (Number) |
---|---|
Ibrutinib+BR | 28.7 |
Placebo+BR | 5.9 |
PFS was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. IWCLL 2008 criteria for PD: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other new organ infiltrates, bone lesion, ascites, or pleural effusion confirmed due to chronic lymphocytic leukemia (CLL); >=50% increase in existing lymph nodes; >=50% increase in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) or >=50% increase from nadir count confirmed on >=2 serial assessments if absolute lymphocyte count (ALC) >=30,000 per microliter and lymphocyte doubling time is rapid, unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b [Hgb] or platelets) attributable to CLL; and transformation to a more aggressive histology. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Months (Median) |
---|---|
Ibrutinib+BR | 65.12 |
Placebo+BR | 14.32 |
The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)
Intervention | Units on the scale (Mean) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lost weight | Dry mouth | Bruises | Abdominal discomfort | Temperature going up and down | Night sweats | Skin problems | Feel ill | Feel lethargic | Felt slowed down | Limited in planning activities | Worried about health in the future | Trouble with chest infections | Trouble with other infections | Repeated courses of antibiotics | Worried about picking up infection | |
Ibrutinib+BR | 0.1 | 0.3 | 0.1 | 0.1 | 0.1 | -0.6 | 0.4 | 0.1 | 0.1 | 0.3 | 0.2 | 0.0 | 0.2 | 0.7 | 0.9 | 0.3 |
Placebo+BR | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | -0.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.2 |
Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (>=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (>)100* 109/liter (L) if baseline less than or equal to (<=) 100*109/L or increase >= 50 percent (%) over baseline; 2) Hemoglobin >11 gram per deciliters (g/dL) if baseline <= 11 g/dL or increase >= 2 g/dL over baseline. (NCT01611090)
Timeframe: Up to 5 years
Intervention | Percentage of Participants (Number) | |
---|---|---|
Hemoglobin | Platelets | |
Ibrutinib+BR | 36.7 | 30.8 |
Placebo+BR | 29.1 | 21.8 |
2 reviews available for adenine and Thrombopenia
Article | Year |
---|---|
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc | 2016 |
Metabolic disorders of platelets.
Topics: Adenine; Blood Platelet Disorders; Blood Platelets; Blood Proteins; Cell Aggregation; Clofibrate; Fi | 1971 |
6 trials available for adenine and Thrombopenia
Article | Year |
---|---|
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxoru | 2022 |
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2020 |
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dr | 2019 |
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atr | 2016 |
A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Imides; Isoquinoline | 1998 |
Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Blood Cell Count; Drug Resistance; Female; Granulocytes | 1991 |
8 other studies available for adenine and Thrombopenia
Article | Year |
---|---|
Sudden Flank Pain in a Patient Receiving Ibrutinib for Mantle Cell Lymphoma.
Topics: Acute Disease; Adenine; Female; Flank Pain; Hematoma; Humans; Kidney Diseases; Lymphoma, Mantle-Cell | 2018 |
Cryoglobulins mimicking platelet recovery in a mantle cell lymphoma patient treated with chemoimmunotherapy.
Topics: Adenine; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochlo | 2015 |
Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia.
Topics: Adenine; Benzoates; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil | 2012 |
[Effect of adenine on thrombopenia induced by experimental benzene poisoning].
Topics: Adenine; Benzene; Blood Platelets; Poisoning; Thrombocytopenia | 1955 |
RELATION OF STORAGE TO THE FUNCTION AND ULTRASTRUCTURAL CHANGES OF TRANSFUSED SURVIVING HUMAN PLATELETS IN THROMBOCYTOPENIC PATIENTS.
Topics: Adenine; Blood Cell Count; Blood Platelets; Blood Preservation; Blood Transfusion; Electrons; Humans | 1964 |
Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Thro | 2006 |
[The MYH9 syndrome: report of a new case with a new mutation of the MYH9 gene].
Topics: Adenine; Adolescent; Exons; Female; Humans; Molecular Motor Proteins; Myosin Heavy Chains; Point Mut | 2006 |
Studies on the platelet defect in alcoholism.
Topics: Adenine; Adenosine Diphosphate; Adenosine Triphosphate; Alcoholism; Autoimmune Diseases; Blood Plate | 1975 |